Moat
86.0/10
Large biologic franchises, global commercialization, regulated manufacturing, clinical evidence, and payer relationships create a strong moat, although mature products such as Enbrel can face meaningful price and access pressure.
AMGNQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 51-75.
Amgen
Amgen is a biotechnology and pharmaceutical company focused on human therapeutics, including biologic medicines for inflammatory, cardiovascular, oncology, bone health, and rare-disease markets.
Metadata
Where this company sits
- Ticker
- AMGN
- Rank snapshot
- ≈ 75
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Region
- United States
- Index
- S&P 500 · Top 75 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
28.0/10
Open discovery tools and biosimilar pathways can decentralize parts of the value chain, but approved biologic replacement still depends on tightly regulated manufacturing, clinical comparability, quality systems, and distribution.
Profitability
79.0/10
Amgen reported $7.711 billion of 2025 net income on $36.751 billion of total revenue, indicating strong profitability despite high R&D, manufacturing, acquisition amortization, and commercialization costs.
Price / Earnings
23.8x
Approximate trailing P/E calculated from a $183.12 billion market cap as of May 22, 2026 divided by 2025 net income of $7.711 billion.
Market cap
$183.1B
StockAnalysis reported Amgen market cap or net worth of $183.12 billion as of May 22, 2026, checked on May 25, 2026.
Freed-up capital potential
$0.0
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business Profile
Amgen develops, manufactures, and markets human therapeutics globally, with a product portfolio led by biologics and specialty medicines. Its 2025 annual report lists $36.751 billion in total revenue and $7.711 billion in net income, with product sales spread across U.S. and rest-of-world markets.
The seeded products, Enbrel and Repatha, illustrate two different moat types: an older high-revenue inflammatory-disease biologic facing net-price pressure, and a growing PCSK9 cardiovascular therapy with expanding volume.
Registry Fit
Amgen belongs in the health-care pharmaceuticals taxonomy because its core asset base is regulated drug discovery, clinical evidence, biologic manufacturing, payer access, and branded therapeutic distribution.
The decentralization question is not whether patients can self-manufacture these drugs today; it is whether open discovery infrastructure, biosimilar pathways, cooperative manufacturing models, and transparent clinical-data networks can reduce dependence on a small number of incumbent biologics sponsors over time.
Moat reading
Amgen's moat is strong because biologic medicines require clinical evidence, regulatory approvals, specialized manufacturing, payer contracting, physician trust, pharmacovigilance, and long-lived intellectual-property and know-how advantages. The company also has scale across roughly 100 countries and a diversified portfolio rather than a single-product business.
The moat is not absolute. Enbrel's 2025 sales decline shows that payer redesign, discounting, biosimilar policy, and mature-product dynamics can pressure even major biologic franchises. Repatha's growth shows the other side of the moat: once outcomes evidence, access, and clinical practice align, a complex injectable therapy can scale globally.
Decentralization reading
Direct decentralized replacement of Amgen's marketed biologics is currently low-readiness because regulated therapeutics cannot be substituted by informal production without proving quality, safety, potency, and clinical comparability. The strongest decentralization pressure comes upstream and around the edges: open target discovery, open molecular tooling, biosimilar regulation, cooperative data generation, and smaller validated manufacturing cells.
For Free The World purposes, Amgen is a high-moat, low-to-moderate decentralizability company. Credible disruption concepts should focus on regulated biosimilar coalitions, open science infrastructure, and verifiable manufacturing or clinical-data coordination rather than pretending that household drug production can replace FDA-approved biologics in the near term.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 4 structured disruption concepts across the current product set.
4 disruption concepts tracked0 documented exceptions
Enbrel
Autoimmune biologic therapy
2 conceptsEnbrel is Amgen's etanercept biologic for inflammatory autoimmune conditions, including rheumatoid arthritis and related diseases.
Repatha
Cardiovascular biologic therapy
2 conceptsRepatha is Amgen's evolocumab PCSK9 inhibitor used to reduce LDL-C and reduce cardiovascular event risk in indicated patients.
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Microfactories and automated mini-home production
Small, software-defined manufacturing cells could make localized production less eccentric and more default.
- • Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
- • Logistics moats still matter, but their margin for arrogance should narrow.
- • Open-source production recipes can pressure both price and product differentiation.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Amgen 2025 Annual Report and Letter to Shareholders
Amgen · annual report
Primary source for 2025 revenue, net income, product sales, product descriptions, and management discussion of Enbrel and Repatha trends.
Reviewed 2026-05-25
Our Products
Amgen · product page
Official product directory confirming Enbrel and Repatha product pages and Amgen's marketed therapeutics footprint.
Reviewed 2026-05-25
Amgen Market Cap
StockAnalysis · market data
Market-data source for Amgen's current market capitalization and ranking context as of May 2026.
Reviewed 2026-05-25
9 Things to Know About Biosimilars and Interchangeable Biosimilars
U.S. Food and Drug Administration · regulatory filing
Regulatory source explaining biosimilars, interchangeability, lower-cost potential, and FDA's role in therapeutic substitution.
Reviewed 2026-05-25
What We Do
Open Insulin · open source project
Open-source biologics manufacturing reference for small-scale production, open techniques, organisms, protocols, and open hardware concepts.
Reviewed 2026-05-25
Open Targets Platform
Open Targets · open source project
Open-source therapeutic target identification platform relevant to decentralized drug-discovery infrastructure.
Reviewed 2026-05-27